Related Experiment Videos
Recent placebo-controlled acute trials in bipolar depression: focus on methodology
David J Muzina1, Joseph R Calabrese
1Cleveland Clinic Foundation, Cleveland, Ohio, USA. muzinad@ccf.org
The International Journal of Neuropsychopharmacology
|September 17, 2003
Summary
Recent trials show lamotrigine monotherapy effectively treats bipolar I depression, outperforming placebo on key scales. Other treatments like paroxetine augmentation and moclobemide offered varied results in managing depressive episodes.
Area of Science:
- Psychiatry
- Neuroscience
- Pharmacology
Background:
- Bipolar I depression management has evolved with new trial designs.
- Early studies used crossover designs; recent trials utilize parallel arms with placebo controls.
Purpose of the Study:
- To evaluate the efficacy of lamotrigine, paroxetine augmentation, and moclobemide in treating bipolar I depression.
- To compare these treatments against placebo using intent-to-treat analyses.
Main Methods:
- Three large-scale, double-blind, randomized controlled trials were conducted.
- Treatments evaluated included lamotrigine monotherapy, paroxetine augmentation, and moclobemide monotherapy.
- Efficacy was assessed using Montgomery-Asberg Depression Rating Scale (MADRS), Clinical Global Impressions (CGI), and 17-item Hamilton Depression Rating Scale (HAMD).
Main Results:
- Lamotrigine monotherapy demonstrated superiority over placebo on MADRS and CGI scales, but not HAMD.
- Paroxetine augmentation showed no overall benefit compared to placebo augmentation.
- Moclobemide monotherapy was comparable to imipramine but had a lower switch rate.
Conclusions:
- Lamotrigine is a viable monotherapy option for bipolar I depression.
- Paroxetine augmentation did not prove superior to placebo in this context.
- Moclobemide offers an alternative with a potentially lower risk of mood switching.